Who we are
Fondazione Humanitas per la Ricerca is a non-profit institution, engaged in the study and treatment of some of the most serious diseases affecting millions of people each year: cancer, heart attacks, strokes, auto-immune, neurological and osteoarticular diseases.
The studies, carried out in collaboration with the Humanitas Group hospitals, aim at quickly implementing research results into treatments, thanks to an ongoing flow of information between laboratory and clinical activity.
Fondazione Humanitas per la Ricerca of today funds over 400 researchers who, together with all hospital doctors, work every day to identify new treatments for patients supported by advanced technology, from genetics to molecular imaging.
To better disseminate its research activity, three projects have been launched:
- Pink Union: addressing women, the prevention and early diagnosis of female pathologies
- Blue One: addressing men, for health and prevention in men
- Argento Vivo: addressing health issues and new treatments for the Silver Generation
In the last few years Humanitas has been introducing increasingly sophisticated Artificial Intelligence tools in its research projects, allowing for faster and more precise solutions.
Prof. Alberto Mantovani
Alberto Mantovani is the President of Fondazione Humanitas per la Ricerca and Scientific Director of the IRCSS Clinical Institute Humanitas. Mantovani has contributed to progress in the immunology sector, both by formulating new paradigms and identifying new molecules and functions. Bibliometric analyses show he ranks amongst the10 most cited immunologists internationally.
He has won many national and international awards for his research activity, including the coveted Pezcoller-AACR prize in May 2019, awarded by the American Association for Cancer Research ‘for his extraordinary results in cancer research’; the Prize for Excellence in Medicine in (American-Italian Cancer Foundation) in 2018; and the European Award for Oncology from the European Organisation for Research and Treatment of Cancer (OECI) and the Robert Koch Award for the wide-ranging impact of his immunological findings on medicine.
Humanitas is at the forefront of Research against Cornavirus, SARS-CoV-2. Over 50 studies were promptly activated aimed at exploring and understanding the virus hence fighting it more effectively.
Among these, a key project led by Professor Mantovani stands out for its research on the importance of some cells which possess innate immunity (a key first line of defence against virus and bacteria) in the resistance and pathogenesis of infection from SARS-CoV-2.
In addition, Humanitas has started the COVID care programme, the largest epidemiological study carried out as of today, involving 4,000 people, which aims to understand the effective development of the immune response (IgG) to Covid-19, among professionals working in Humanitas Groups branches in Lombardia, Italy.
The first results were made publicly available, to allow the scientific community to access the data, and to demonstrate that hospitals, if appropriately protected, can be safe places.
Support Scientific Research: it’s simple
With a bank transfer
SWIFT Code: BPMOIT22XXX
BPER Banca S.p.A.
Headed to: Fondazione Humanitas per la Ricerca